海思科：HSK44459片新增适应症IND申请获受理

Core Viewpoint - The company has received a notice from the National Medical Products Administration regarding the acceptance of the clinical trial application for HSK44459 tablets, aimed at treating inflammatory bowel disease [1] Group 1: Product Development - HSK44459 tablets are independently developed by the company for the treatment of inflammatory bowel disease [1] - Preclinical research results indicate that HSK44459 has independent intellectual property rights, confirmed efficacy, and good safety [1] Group 2: Clinical Trials - HSK44459 tablets have already received clinical trial approval notices for other indications, including interstitial lung disease, Behçet's disease, psoriasis, and atopic dermatitis, all of which are currently undergoing Phase II clinical studies [1]